scispace - formally typeset
Open AccessJournal ArticleDOI

Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors.

R. Charlier
- 01 Aug 1970 - 
- Vol. 39, Iss: 4, pp 668-674
Reads0
Chats0
TLDR
It is concluded that the cardiac actions of amiodarone are not produced by competitive blockade of β‐adrenoceptors.
Abstract
1. The cardiac actions of amiodarone, a benzofuran derivative used in the treatment of angina pectoris, have been compared with those of (±)-propranolol in anaesthetized dogs. 2. After three successive intravenous injections of propranolol, 0·5 mg/kg, had reduced the heart rate by 25%, a fourth dose had no further negative chronotropic action, but amiodarone, 10 mg/kg intravenously, at this point reduced the heart rate by 23%. 3. Amiodarone, 10 mg/kg intravenously, reduced, but did not abolish, cardiac responses to isoprenaline, 2 μg/kg intravenously. Subsequent successive injections of 10 mg/kg of amiodarone did not further block the responses to isoprenaline, but propranolol, 1 mg/kg intravenously, abolished them. 4. Amiodarone reduced cardiac chronotropic and inotropic responses to glucagon, which were not affected by propranolol. 5. Cardiac output was increased 5 min after amiodarone, 10 mg/kg intravenously, but at 10 min and thereafter it did not differ from control values. Propranolol, 1 mg/kg intravenously, reduced cardiac output by 17% at 5 min, and by 30% after 30 min. 6. From this and other evidence which is discussed, it is concluded that the cardiac actions of amiodarone are not produced by competitive blockade of β-adrenoceptors.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia.

TL;DR: In this paper, the hemodynamic effects of amiodarone were evaluated under oral loading (1000 mg/day for 14-16 days) and during chronic treatment (600 mg/Day for a further 10 weeks) in 15 patients with recurrent ventricular tachycardia.
Journal Article

Efeito da administração prévia de amiodarona na incidência precoce de fibrilação ventricular durante isquemia miocardia experimental

TL;DR: Results mostram that a administracao previa de amiodarona reduziu expressivamente a incidencia precoce de FV apos oclusao coronaria e levantam a possibilidade de sua utilizacao clinicoprofilatica em situacoes em que o risco de isquemia miocardica seja iminente.
Journal ArticleDOI

Amiodarone Offsets the Cardioprotective Effects of Ischaemic Preconditioning against Ischaemia/Reperfusion Injury

TL;DR: All of the myocardial protective effects against ischaemia/reperfusion injury were diminished or abolished when IPC and amiodarone were applied sequentially.
Journal ArticleDOI

[Amiodarone therapy--behavior of serum and fatty tissue concentrations].

TL;DR: In this paper, a high-pressure liquid chromatography method was used to measure serum and subcutaneous fatty tissue concentrations of amiodarone and its metabolite desethylamidarone after one week, one month, three months, and then at 6-month intervals.
Journal ArticleDOI

Absence of prejunctional sympathetic effect of amiodarone in hearts of open-chest anesthetized dogs.

TL;DR: It is concluded that amiodarone, administered orally for 3 weeks, does not interfere with neural NA release, or with the positive inotropic response, following sympathetic nerve stimulation in dogs.
References
More filters
Journal ArticleDOI

A study of the adrenotropic receptors

TL;DR: Experiments described in this paper indicate that although there are two kinds of adrenotropic receptors they cannot be classified simply as excitatory or inhibitory since each kind of receptor may have either action depending upon where it is found.
Journal ArticleDOI

The effect of amiodarone, a new anti‐anginal drug, on cardiac muscle

TL;DR: It was concluded that amiodarone had effects on cardiac action potentials similar to those which occur after thyroidectomy.
Journal ArticleDOI

Glucagon Its Enhancement of Cardiac Performance in the Cat and Dog and Persistence of its Inotropic Action Despite Beta-Receptor Blockade with Propranolol

TL;DR: In the dog, myocardial performance was markedly augmented by the administration of glucagon, 50 μg/kg iv, as indicated by an average increase of 72.2±18.8% in force recorded by a strain gauge arch, despite an average decrease of 3.8±1.2 cm H2O (P < 0.02) in left ventricular end-diastolic pressure.
Journal ArticleDOI

Cardiac Actions of Glucagon

TL;DR: The results of these studies are discussed in reference to the known metabolic actions of glucagon and the catecholamines and the possibility that they both share a common mechanism of action mediated through an increase in the intracellular concentration of cyclic 3′,5′ AMP.
Related Papers (5)